We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prevalence of metabolic syndrome, characteristics of metabolic syndrome and relationship with the antipsychotics used in schizophrenia.
- Authors
Kaya MC; Virit O; Altindag A; Selek S; Bülbül F; Bulut M; Savas HA
- Abstract
Objective: In this cross-sectional study we aimed to determine the metabolic syndrome (MetS) prevalence in schizophrenia patients followed up in our Psychotic Disorders Unit, and to evaluate the relationship between MetS and medication of the patients. Method: High density lipoprotein (HDL), fasting glucose, triglyceride levels, arterial blood pressure and waist circumference at the level of the umbilicus of the patients included in the study were measured in 87 schizophrenia patients. Results: According to Adult Treatment Panel III (ATP III), ATP III A and International Diabetes Federation (IDF) criteria; metabolic syndrome prevalence was 29.9%, 35.6% and 42.5% respectively. 27.6% of patients had two criteria of MetS but did not meet MetS diagnosis. There was no association between MetS and age, age of onset of illness and duration of illness. Men had higher MetS prevalence according to all diagnostic criteria, however there was a statistical significance only for IDF. There was no difference of MetS prevalence between monotherapy and combined antipsychotic medications. The metabolic syndrome prevalence was significantly lower in biperiden users than in the nonuser patients Discussion: Although the prevalence of MetS is lower than in some previous studies, it is generally similar to other schizophrenia researches. MetS must be carefully considered in schizophrenia patients' follow up and treatment choices, and some risk decreasing interventions must be made when necessary in the early period.
- Publication
Archives of Neuropsychiatry / Nöropsikiyatri Arşivi, 2009, Vol 46, Issue 1, p13
- ISSN
1300-0667
- Publication type
Journal Article